BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28627153)

  • 1. [Implementation of DNA-HPV primary screening in Italian cervical cancer screening programmes. Results of the MIDDIR Project].
    Di Stefano F; Giorgi Rossi P; Carozzi F; Ronco G; Cacciani L; Vecchi S; Naldoni C; Segnan N;
    Epidemiol Prev; 2017; 41(2):116-124. PubMed ID: 28627153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study].
    Depetrini E; Bonelli L; Ardoino S; Cirucca MC; Contin R; De Leonardis D; Errigo V; Lugani A; Franco A; Pastorino A; Carrozzi G; Venturino E
    Epidemiol Prev; 2016; 40(3-4):171-8. PubMed ID: 27436250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
    Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
    Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical implementation of primary HPV screening.
    Mariani L; Igidbashian S; Sandri MT; Vici P; Landoni F
    Int J Gynaecol Obstet; 2017 Mar; 136(3):266-271. PubMed ID: 28099686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability and feasibility of a community based participatory research project comparing cytology and urine HPV DNA testing for cervical cancer screening in Yap, Federated States of Micronesia.
    Sy AU; Hernandez BY; Tareg A; Reichhardt M; Buenconsejo-Lum L
    Cancer Epidemiol; 2017 Oct; 50(Pt B):283-288. PubMed ID: 29120838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rationale for implementation of HPV testing in routine cervical screening in Romania.
    Iancu LS; Ursu RG
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):293-6. PubMed ID: 24340506
    [No Abstract]   [Full Text] [Related]  

  • 9. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
    Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indicators for monitoring screening programs with primary HPV test.
    Zorzi M; Giorgi Rossi P;
    Epidemiol Prev; 2017; 41(1 Suppl 1):1-32. PubMed ID: 28322534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecologists and human papillomavirus DNA testing: exploring knowledge, attitudes, and practice in Italy.
    Caglioti C; Pileggi C; Nobile CG; Pavia M
    Eur J Cancer Prev; 2017 May; 26(3):249-256. PubMed ID: 27879494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
    Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
    Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Squamous cell carcinoma of the cervix: a cytology-histology-human papillomavirus correlation in clinical practice.
    Miller RA; Waters LL; Mody DR; Tams KC
    Arch Pathol Lab Med; 2015 Jun; 139(6):776-81. PubMed ID: 26030246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
    Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
    Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Socio-economic variations in anticipated adverse reactions to testing HPV positive: Implications for the introduction of primary HPV-based cervical screening.
    O'Connor M; O'Leary E; Waller J; Gallagher P; Martin CM; O'Leary JJ; Sharp L;
    Prev Med; 2018 Oct; 115():90-96. PubMed ID: 30144488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
    Cubie HA; Moore C; Waller M; Moss S;
    J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
    Petry KU; Barth C; Wasem J; Neumann A
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.